American Century Companies Inc. Increases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

American Century Companies Inc. grew its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 46.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 135,592 shares of the company's stock after acquiring an additional 43,123 shares during the period. American Century Companies Inc. owned about 0.29% of Pacira BioSciences worth $2,555,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Caitlin John LLC lifted its holdings in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after buying an additional 1,776 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after acquiring an additional 513 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after buying an additional 918 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Pacira BioSciences in the 4th quarter valued at $190,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PCRX shares. HC Wainwright lifted their price target on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday. Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Pacira BioSciences in a research note on Tuesday. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and upped their price target for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada reissued a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Barclays upped their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences has a consensus rating of "Hold" and a consensus target price of $26.67.

Pacira BioSciences Stock Up 3.7 %

Shares of NASDAQ PCRX traded up $0.87 during mid-day trading on Friday, hitting $24.56. The company had a trading volume of 605,564 shares, compared to its average volume of 969,947. The business's 50-day simple moving average is $24.74 and its 200 day simple moving average is $20.81. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a market capitalization of $1.14 billion, a PE ratio of -12.10 and a beta of 0.71.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.